Although patients receiving chemotherapy are at high risk for influenza due to their compromised immune function, it does not mean that influenza vaccination during chemotherapy is inappropriate. On the contrary, "Clinical Practice Guideline of Breast Cancer by The Japanese Breast Cancer Society" actually recommends vaccination based on scientific evidence

As myelosuppression is a side effect of anticancer drugs such as TS-ONE ^® , patients’ bone marrow and immune functions should be assessed.

Tegafur is a prodrug, and thus is relatively safe among anticancer drugs, and there appears to be no influence of occupational exposure to the drug during the dispensing procedure, etc. Nevertheless, it is important to carefully handle the drug in accordance with in-house guidelines for handling drugs or other guidance.

10 hours of dosing interval for TS-ONE ^® is advised in terms of the blood kinetics of 5-FU, the principal component to show efficacy and safety.

If forgot to take medicine, the missed dose should be skipped and take the dose at next scheduled time.

There is no report of the exact determination of the blood concentration of drug contained in the sweat or saliva of humans after administration of TS-ONE ^® .

However, if the concentration in the above body fluids is similar to the plasma concentration, the total amount of 5-FU after exposure to 10 mL of body fluid would become about 1 µg. This amount is very small, so it is considered less possible that any toxicity would be induced by exposure to the drug through these body fluids in usual contact.

Based on the above, we have not requested any special precautions for exposure to family members.

It is not advisable to re-divide decapsulated TS-ONE ^® .

The slight declining of absorption speed (Cmax, Tmax) of tegafur was observed whereas no declining in AUC was confirmed.

In the case of usual hair loss, hair matrix cells are not completely damaged and lost. Therefore, hair loss associated with anticancer drugs is believed to be transient and reversible, with new hair regrowing from hair follicles after approximately 6 months. However, as outcomes may differ between individuals depending on the extent of damage to hair matrix cells, it is impossible to determine how long recovery will take.

Tubal administration of TS-ONE ^® via a gastric fistula is considered allowed.

As TS-ONE ^® is designated as a powerful drug, caution is required for decapsulation. As a maximum of 3% will be lost by decapsulation, decapsulation should be performed carefully.